as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹181.66
Change
+7.28 (4.17%)
Open
₹173.2
Prev. Close
₹174.38
Day High
₹183.0
Day Low
₹170.25
Volume Analysis
Traded
278,889
Delivered
100,527
Delivery %
36.05%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (76.5%)
- •Promoter holding is rising
Weaknesses (2)
- •High debt-to-equity ratio (1.51)
- •Below-average fundamentals quality score (42/100)
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹199.1 | ₹191.05 | ₹186.35 | ₹178.3 | ₹173.6 | ₹165.55 | ₹160.85 |
| Fibonacci | ₹191.05 | ₹186.18 | ₹183.17 | ₹178.3 | ₹173.43 | ₹170.42 | ₹165.55 |
| Camarilla | ₹185.17 | ₹184.0 | ₹182.83 | ₹178.3 | ₹180.49 | ₹179.32 | ₹178.15 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-20.99%
1 Week
-9.14%
1 Month
-3.2%
3 Months
-31.41%
6 Months
-35.91%
1 Year
-21.1%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
21.83%
Net margin 5.17% × asset turnover 1.16x × equity multiplier 3.64x
Company Overview
Sector
Healthcare
Market Cap
₹676 Cr
P/E (TTM)
20.3
ROE
76.5%
Book Value
₹44.9
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Wanbury Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 42/100. The strongest factor is Business Quality (67/100), while Momentum (16/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (76.5%); promoter holding is rising; high debt-to-equity ratio (1.51); below-average fundamentals quality score (42/100). FII holding has been rising.
TopFund Score — Fundamentals Quality
42/100 — WeakData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 30.9% CAGR over last 5 years
- −Though the company is reporting repeated profits, it is not paying out dividend
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of 10.3% over past five years.
- −Tax rate seems low
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Wanbury received ANVISA CADIFA approval for Metformin HCl EP grade; third consecutive API approval.
Wanbury reported Q2 FY27 revenue of Rs 182.9 crore and PAT of Rs 11.9 crore, plus approvals and launches.
Wanbury approved Q2 and H1 FY2027 results; formed Wanbury Skin Health subsidiary, commenced October 2026.
Tanuku plant received Australian TGA GMP certificate on 28 October 2026, valid until 9 December 2028.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 124 | 126 | 133 | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 | 183 |
| Expenses + | 118 | 119 | 119 | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 | 160 |
| Operating Profit | 6 | 6 | 14 | 13 | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 | 23 |
| OPM % | 4.52% | 5.13% | 10.64% | 9.13% | 12.0% | 14.54% | 13.03% | 8.37% | 12.41% | 10.45% | 17.23% | 14.98% | 12.43% |
| Other Income + | 1 | 0 | -3 | 1 | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 | 0 |
| Interest | 4 | 7 | 8 | 6 | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 | 6 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 | 12 |
| Tax % | 25.35% | 7.54% | -10.87% | 6.0% | -2.5% | -0.19% | 0.8% | 0.0% | 1.84% | 5.38% | -6.3% | 0.88% | 30.99% |
| Net Profit + | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 | 9 |
| EPS in Rs | 0 | -1 | 0 | 1 | 2 | 3 | 10 | 0 | 2 | 0 | 6 | 4 | 2 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 0 | 1 | -1 | 25 | 17 | 16 | 5 | -10 | 12 | -8 | 23 | 24 | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Sep 2014 18m | Mar 2015 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 600 |
| Expenses + | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 484 | 520 |
| Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 80 |
| OPM % | 3.7% | 9.0% | 8.0% | 4.3% | -18.0% | 4.1% | 6.0% | 4.7% | 7.0% | 5.0% | 13.0% | 13.0% |
| Other Income + | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 26 | 0 |
| Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 |
| Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 |
| Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 |
| Tax % | 2.0% | 28.0% | 0.0% | 1.0% | -1.0% | -1.0% | 0.0% | 2.0% | 0.0% | 1.0% | 1.0% | -3.0% |
| Net Profit + | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 |
| EPS in Rs | -64 | 2 | -4 | 27 | -13 | -10 | 26 | -5 | 25 | -3 | 17 | 9 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Sales growth | 44 | — | 68 | 3 | -14 | 6 | -6 | 7 | 30 | -5 | 15 | 8 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -5 | 26 | 122 |
| Borrowings + | 389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | 179 | 237 |
| Other Liabilities + | 209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 199 | 176 | 178 |
| Total Liabilities | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 | 572 |
| Fixed Assets + | 174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 | 262 |
| CWIP | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 | 17 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 174 | 208 | 292 |
| Total Assets | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 | 572 |
| Equity Capital | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 | 35 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | 26 |
| Cash from Investing Activity + | -6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | -51 |
| Cash from Financing Activity + | -71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | 26 |
| Net Cash Flow | -9 | 5 | -5 | 3 | -2 | 0 | 0 | 7 | 13 | -21 | 2 | 1 |
| Free Cash Flow | 56 | 35 | 22 | 29 | 30 | 25 | 36 | 12 | 42 | 7 | -10 | -23 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 278 | 188 | 129 | 234 | -49 | 188 | 188 | 97 | 113 | 76 | 6 | 33 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 60.2% | 60.02% | 59.97% | 59.21% | 59.4% | 58.68% | 58.79% | 56.08% | 56.21% | 56.39% | 56.04% | 56.28% |
| Promoters | 39.79% | 39.79% | 39.79% | 39.77% | 39.76% | 39.76% | 39.63% | 43.09% | 43.08% | 43.01% | 43.01% | 42.98% |
| FII | 0.0% | 0.18% | 0.22% | 1.02% | 0.84% | 1.55% | 1.59% | 0.82% | 0.72% | 0.59% | 0.89% | 0.71% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.06% | 0.02% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Wanbury Limited (this stock) | 676 | 20.3 | 4.3 | 76.5% |
| Rays Of Belief Limited | 615 | 99.3 | 4.03 | 16.1% |
| Gaudium Ivf N Women H L | 740 | 32.0 | 4.55 | 24.6% |
| Fabtech Technologies Ltd | 609 | 20.5 | 1.39 | 12.0% |
| Zim Laboratories Limited | 756 | 365.0 | 2.59 | 1.59% |
| Valiant Laboratories Ltd | 570 | 35.2 | 1.72 | -2.55% |
| Shree Ganesh Remedies Ltd | 798 | 65.9 | 4.79 | 10.8% |
Which Mutual Funds Hold Wanbury Limited?
Frequently Asked Questions about Wanbury Limited
Wanbury Limited (WANBURY) closed at ₹181.66 on NSE on 19 November 2026, up 7.28 (4.17%) from the previous close.
Wanbury Limited trades on the NSE (National Stock Exchange of India) under the symbol WANBURY.
Wanbury Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 20.3.
Wanbury Limited has a dividend yield of 0.0%.
Wanbury Limited's 52-week high is ₹360.0 and its 52-week low is ₹162.0.
Wanbury Limited has a market capitalisation of ₹676 crore.
Wanbury Limited has a TopFund Quality Score of 42/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Wanbury Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.